Westminster Health Forum

Since lockdown, we have been organising our full programme of conferences online. We will continue online until further notice, to ensure we play our part in helping our employees and delegates to remain safe during this time. We are pleased that so many key stakeholders, policymakers and other interested parties - both old friends and new delegates - are taking up the opportunity to discuss public policy issues and network at our impartial seminars. New events are coming on to our conference programme all the time. So there are plenty of opportunities for you to join us if you haven’t already, from wherever you are. For booking-related queries, or information on speaking, please email us at info@forumsupport.co.uk or contact us using one of the following numbers: +44 (0)7538736244 / +44 (0)7503591880 / +44 (0)7951044809.
For delegates already booked on, we will send you the online joining instructions (including links, event numbers and passwords) five working days before your conference. If you cannot find these in your inbox please email delegate.relations@forumsupport.co.uk

The future for NICE in health and social care - new evaluation processes, keeping pace with developments, and improving patient access to innovation

Morning, Monday, 25th January 2021


***Full-scale policy conference taking place online***

This conference will discuss the future priorities and role of NICE in health and social care, and the next steps for accelerated access to innovative health technologies.


We are delighted that Professor Gillian Leng, Chief Executive, NICE has agreed to deliver a keynote address at this conference.


The discussion is bringing together stakeholders with further key policy officials who are due to attend from the DHSC; the MHRA; DIT; and The Scottish Government.


The agenda:

  • Priorities for NICE and responding to the changing health and social care landscape
  • The future role for NICE in health and social care - evidence-based guidelines, patient involvement, utilising data, ensuring patient safety, and lessons from the response to COVID-19
  • Supporting the development and adoption of innovative medicine
  • Adapting NICE processes to enable effective delivery of new technologies
  • Improving patient access to innovation - new approaches to evaluating health technologies, speed and safety, growing capacity, and managed access and fair pricing
  • Next steps for NHS collaboration with NICE

A scan of relevant developments:

  • NICE’s methods of technology evaluation - presenting a case for change - consultation methods used in Tas, assessing highly specialised technologies, and how guidance is produced
  • NICE & SIGN announce latest rapid COVID-19 guideline will address Long COVID - work around long term health effects from COVID-19, also involving the RCGP
  • NICE’s support for rebuilding capacity in non-COVID health services - outlining the approach to help manage the backlog and support the restoration of services
  • Independent Medicines and Medical Devices Safety Review report - with a number of general and specific recommendations affecting NICE
  • NHS Long Term Plan and the Life Sciences Sector Deal - with commitments on increasing and speeding up NICE appraisals
  • Genome UK: the future of healthcare - the new national genomic healthcare strategy recently launched

The discussion in detail:

  • COVID-19:
    • during the crisis - assessing the role played by NICE, the impact of its single point of access for national advice on COVID-19, and learning from the process of providing rapid guidelines through the pandemic that seek to prioritise both safety and speed of response
    • moving forward - how NICE can support clinicians caring for patients with long term effects from COVID-19, and help with backlog and restoration of services
  • funding - assessing the impact and adequacy of funding through the Life Sciences Sector Deal 2 for ramping up NICE appraisal capacity
  • effectiveness:
    • use of data and next steps for developing evidence-based guidance
    • ensuring that the NICE approach and its outputs reflect advances in science, and the changing health and care landscape in areas such as increased integration and personalisation
    • what actions NICE can take - in collaboration with other public bodies, policymakers and stakeholders where required - to reinforce the need for its guidance to be closely followed 
  • new technologies - developing evidence-based guidelines for advances such as genomics - with discussion expected on:
    • next steps for developing methods for evaluating new treatments and enabling fast patient access to new care developments
    • approaches to pricing and ensuring cost-effectiveness
    • priorities for taking a collaborative approach and early engagement with the new technologies, including the involvement of patients
    • how NICE can provide guidance and methods to support developments around personalised care
  • the NICE review into how it holds appraisals in health technology and highly specialised technology:
    • the present position - assessing current NICE approaches to appraisals in this area
    • options for change - to what extent methods need to be updated and the changes to methods and processes required
    • keeping pace - how it can remain up to date with a changing health and care policy landscape
  • patient access to innovation - the role of NICE in delivering improvements going forward, with discussion including:
    • what lessons can be taken from the response to COVID-19 in terms of accelerating processes and working collaboratively
    • opportunities for managed access, the progress of the Cancer Drugs Fund and the prospects and possibilities for building on this with an Innovative Medicines Fund
    • overcoming barriers and the progress of the Accelerated Access Collaborative
    • improvements, lessons and opportunities that have arisen from the Voluntary Scheme for Branded Medicines Pricing and Access as the scheme nears its third year
    • the capacity of NICE to deal with increased appraisals
    • ensuring patient safety
    • next steps for NHS collaboration with NICE

Policy officials attending:

Our forums are known for attracting strong interest from policymakers and stakeholders. Places have been reserved by the DHSC; the Department of International Trade; the MHRA; and The Scottish Government.


Overall, we expect speakers and attendees to be a senior and informed group including Members of both Houses of Parliament, senior government and regulatory officials involved in this area of policy, as well as from the NHS and private health providers, executive agencies including clinical staff, regulators, pharmaceutical companies, medical technology companies, the independent and third sectors, patient groups, local authorities, research and development, law firms, consultancies, and others affected by the issues discussed as well as academics and think tanks, together with reporters from the national and specialist media.


This is a full-scale conference taking place online***

  • full, four-hour programme including comfort breaks - you’ll also get a full recording to refer back to
  • information-rich discussion involving key policymakers and stakeholders
  • conference materials provided in advance, including speaker biographies
  • speakers presenting via webcam, accompanied by slides if they wish, using the Cisco WebEx professional online conference platform (easy for delegates - we’ll provide full details)
  • opportunities for live delegate questions and comments with all speakers
  • a recording of the addresses, all slides cleared by speakers, and further materials, is made available to all delegates afterwards as a permanent record of the proceedings
  • delegates are able to add their own written comments and articles following the conference, to be distributed to all attendees and more widely
  • networking too - there will be opportunities for delegates to e-meet and interact - we’ll tell you how!

Full information and guidance on how to take part will be sent to delegates before the conference



Keynote Speakers

Professor Gillian Leng

Chief Executive, NICE

Professor Matthew Cripps

Director of Sustainable Healthcare, NHS England and NHS Improvement

Speakers

Professor Andrew Briggs

Professor of Health Economics, Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine

Gordon Lundie

Senior Director, Market Access, Gilead

Professor Brendan Delaney

Chair in Medical Informatics and Decision Making, Imperial College London

Eleonora Harwich

Director of Research and Head of Digital and Tech Innovation, Reform

Tess Harris

Chief Executive, Polycystic Kidney Disease Charity

Dr Sonia MacLeod

Researcher, Independent Medicines and Medical Devices Safety Review

Ben Richardson

Managing Partner, Carnall Farrar

Luella Trickett

Director, Value and Access, ABHI